Home > Result Summaries: Compounds > fosamprenavir > Result Summary for APV10031

Result Summary for APV10031

Result Summary

Protocol ID:	APV10031
Clinical Study ID:	APV10031
Official Title:	A Phase I, Randomized, Open Label, Two Arm, Three Period, Drug-Drug Interaction Study Comparing Steady-State Plasma Amprenavir and Esomeprazole Pharmacokinetics following Coadministration of GW433908 1400mg BID and Esomeprazole 20mg QD and following Coadministration of GW433908 700mg BID + RTV 1 ...
Phase:	Phase 1
Study Indications or Diseases:	Infection, Human Immunodeficiency Virus
Generic Name:	fosamprenavir
Trade/Product Name:	Telzer,Telzir,Lexiva
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	MJ Shelton, SL Ford, MB Wire, Y Lou, J Borland, S Min, Z Xue, GJ Yuen. Coadministration of Esomeprazole (ESO) with Fosamprenavir (FPV) Has No Impact on Steady-state Plasma Amprenavir (APV) Pharmacokinetics (APV10031). 6th International Workshop on Clinical Pharmacology of HIV Therapy, 28 - 30 April, Québec City, Quebec, Canada (Poster 2.17)